Baidu
map

Nature:异质性的Notch信号促进小细胞肺癌

2017-05-15 zhangfan MedSci原创

部分小细胞肺癌患者通过Notch信号通路激活生成独特的微环境, Notch信号可以作为小细胞肺癌患者预计化疗效果的生物标志物

跨膜受体蛋白Notch信号通路的活性在决定细胞命运(包括增殖、分化以及凋亡)过程中发挥着重要作用,其既可以抑制肿瘤也可以致癌。在肺发育过程中,Notch通路激活可抑制前体细胞向神经内分泌分化。在大部分小细胞肺癌中,Notch基因突变的功能丧失以及异位Notch激活表现出肿瘤抑制作用。

最新研究发现,有10-50%小鼠肺癌模型或人类肿瘤细胞发生Notch途径内源性激活导致发生神经内分泌向非神经内分泌转化,这种转化由转录抑制因子Nrsf介导,抑制神经内分泌基因表达。非神经内分泌Notch激活小细胞肺癌细胞生长缓慢,但对化疗不敏感并且向内分泌肿瘤细胞提供营养支持,表现出致癌作用。更为关键的是,临床前模型发现Notch可阻断化疗对肿瘤生长的抑制和复发延缓作用。

研究发现,部分小细胞肺癌患者通过Notch信号通路激活生成独特的微环境, Notch信号可以作为小细胞肺癌患者预计化疗效果的生物标志物。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-06-11 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-17 karmond
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-17 ymljack
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-16 137****4081

    本质源创性研究很厉害了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-15 中医痴

    学习了!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1882031, encodeId=1fac1882031e6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jun 11 03:09:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068307, encodeId=acba206830e8b, content=<a href='/topic/show?id=90b8129e7bd' target=_blank style='color:#2F92EE;'>#Notch信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12977, encryptionId=90b8129e7bd, topicName=Notch信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jan 09 14:09:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373756, encodeId=0df413e375669, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487443, encodeId=cbe6148e4430a, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Wed May 17 03:09:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198592, encodeId=e16a198592dd, content=本质源创性研究很厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEZQLsqPsCbsOnBS1AERT05H5eKZXUPMd8o1fzdcmdLAGj7j0Z5ia7qvh5a4ziakicAQkKsFGwmJLA0/0, createdBy=3caa2052896, createdName=137****4081, createdTime=Tue May 16 05:28:57 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198359, encodeId=c6c719835957, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon May 15 12:27:03 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198357, encodeId=c54f19835e78, content=疾病的本质真相逐渐被人类发现,预防疾病就不远了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon May 15 12:25:53 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-15 清风拂面

    疾病的本质真相逐渐被人类发现,预防疾病就不远了

    0

相关资讯

Cancer Cell:小细胞肺癌竟然也可以进行分子分型,指明精准治疗未来方向

美国犹他大学的一项新研究发现小细胞肺癌可以再细分为不同的肿瘤亚型,他们还发现一个靶向药物组合对其中一种肿瘤亚型有很好的治疗效果。相关研究结果发表在国际学术期刊Cancer Cell上。这些结果表明不能将不同的小细胞肺癌当作同一种疾病进行治疗。犹他大学的Trudy G. Oliver教授领导了该研究,她表示:“现在医院在接收了小细胞肺癌病人以后不会对他们进行基因检测。他们被诊断为小细胞肺癌之

The Lancet Oncology:预防性全脑照射对特定的广泛期小细胞肺癌无效

预防性全脑照射对初始化疗有效和定期接受MRI且证实无脑转移的广泛期小细胞肺癌患者是不必要

盘点非小细胞肺癌的靶向药物

目前,治疗非小细胞肺癌的靶向药物有 16 种,是所有癌种中靶向药物最多的癌种。抗体类大分子靶向药物有 6 种,小分子靶向药物有 10 种。CFDA 批准在中国上市的有 5 种,包含 4 种小分子靶向药物,1 种大分子靶向药物。从每年 FDA 批准上市的靶向药物的数量可以看出,从 2011 年开始几乎每年都会有针对肺癌的靶向药物上市,2014 年非小细胞肺癌的靶向药物上市数量达到了历史峰值,有

小细胞肺癌的症状、治疗和预防措施

肺癌通常有两种主要形式:小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC),通常来说,NSCLC 更常见,但是其预后比 SCLC 好。与 SCLC 相关的癌细胞比较小,并且肿瘤进展相对较快,这使得该种肿瘤在早期检测和诊断中具有很强的挑战性。

Lancet子刊:Rovalpituzumab tesirine作为DLL3靶向药物抗小细胞肺癌安全有效

δ样蛋白3(DLL3)是一种初始肿瘤细胞中表达的新型靶标蛋白,且这种蛋白在80%以上的小细胞肺癌患者中表达。Rovalpituzumab tesirine是针对这种蛋白的一类新型抗体-药物偶联物。此试验的目的是评估Rovalpituzumab tesirine用于一线或多线治疗失败后小细胞肺癌患者的有效性及安全性。

是什么又让血液检测登上Nature Medicine?

本周发表在Nature Medicine杂志上的一项新研究表明,血液检测能预测小细胞肺癌患者对治疗有何反应。大多数的小细胞肺癌患者在治疗初期产生化疗敏感性,但随后病情会再度恶化。对于少数患者,治疗不到3个月就会出现恶化,这种情况也被称为耐药性。然而,目前区分化疗敏感性和化疗耐药性的分子机制仍是未知的。为了确定化疗敏感性和化疗耐药性的遗传特征,曼彻斯特大学癌症研究中心的科学家从31位侵袭性小细胞肺癌

Baidu
map
Baidu
map
Baidu
map